ARTH:OTC-Arch Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 0.10

Change

0.00 (0.00)%

Market Cap

USD 0.02B

Volume

0.31M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company was founded in 2006 and is based in Framingham, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

N/A

USD232.77B 33.69 3.82
CSLLY CSL Limited

N/A

USD102.96B 43.12 33.30
CMXHF CSL Limited

N/A

USD100.49B 42.32 33.30
WXXWY WuXi Biologics (Cayman) Inc

N/A

USD66.75B 157.50 26.80
WXIBF WuXi Biologics (Cayman) Inc

N/A

USD65.47B 154.50 26.80
GNMSF Genmab A/S

N/A

USD27.56B 69.69 8.47
UCBJF UCB SA

N/A

USD20.72B 18.49 14.40
UCBJY UCB SA

N/A

USD20.60B 19.04 14.40
SBHMY Sino Biopharmaceutical Limited

N/A

USD16.22B 10.62 2.12
SBMFF Sino Biopharmaceutical Limited

N/A

USD16.16B 10.26 2.18

ETFs Containing ARTH

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -35.96% 25% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -35.96% 24% F 17% F
Trailing 12 Months  
Capital Gain -44.51% 22% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -44.51% 22% F 14% F
Trailing 5 Years  
Capital Gain -83.60% 30% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -83.60% 30% F 12% F
Average Annual (5 Year Horizon)  
Capital Gain -28.14% 5% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -28.14% 5% F 2% F
Risk Return Profile  
Volatility (Standard Deviation) 24.76% 93% A 74% C
Risk Adjusted Return -113.67% 2% F 1% F
Market Capitalization 0.02B 51% F 39% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 37.49 16% F 5% F
Price / Cash Flow Ratio -4.50 55% F 72% C-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -4,014.80% 1% F 0% N/A
Return on Invested Capital 503.93% 94% A 98% A+
Return on Assets -91.79% 30% F 11% F
Debt to Equity Ratio -9.25% 71% C- 87% B+
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta -0.25 85% B 88% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector